AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39382222 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily screening and T-piece SBT
Number of subjects: 797
Study 39382222 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent screening and pressure-supported SBT
Number of subjects: 797
Study 39382222 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent screening and T-piece SBT
Number of subjects: 797
Study 39382222 — intervention group
Group type: COMPARATOR
Intervention: More frequent screening vs once-daily screening with pressure-supported SBT
Number of subjects: 797
Study 39382222 — intervention group
Group type: COMPARATOR
Intervention: Once-daily screening and pressure-supported SBT vs T-piece SBT
Number of subjects: 797
Study 39382234 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal blood purification (EBP) device connected to the CPB circuit
Number of subjects: 343
Study 39382234 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 343
Study 39382244 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote daily multidisciplinary rounds led by a board-certified intensivist through telemedicine, monthly audit and feedback meetings, provision of evidence-based clinical protocols.
Number of subjects: 17024
Study 39382244 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 17024
Study 39382244 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (daily multidisciplinary rounds).
Number of subjects: 17024
Study 39382241 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusion triggered by hemoglobin <9 g/dL; n=408)
Number of subjects: 850
Study 39382241 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion triggered by hemoglobin <7 g/dL; n=442)
Number of subjects: 850
Study 39382241 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 850
Study 39382241 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 850
Study 39382446 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-angiogenesis therapy
Number of subjects: 0
Study 39382446 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line anti-angiogenesis therapy
Number of subjects: 0
Study 39382587 — intervention group
Group type: EXPERIMENTAL
Intervention: Red LED
Number of subjects: 0
Study 39382587 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared LED
Number of subjects: 0
Study 39382587 — intervention group
Group type: EXPERIMENTAL
Intervention: LED associated
Number of subjects: 0
Study 39382587 — intervention group
Group type: COMPARATOR
Intervention: Control (G-C)
Number of subjects: 0
Study 39382718 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 67
Study 39382718 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab-chemotherapy
Number of subjects: 67
Study 39382718 — intervention group
Group type: COMPARATOR
Intervention: EXTREME
Number of subjects: 67
Study 39382852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF) from the first day of 33 gestational weeks to delivery (expected 8 weeks)
Number of subjects: 239
Study 39382852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF) from the first day of 33 gestational weeks to 4 weeks postpartum (expected 12 weeks)
Number of subjects: 239
Study 39382852 — intervention group
Group type: COMPARATOR
Intervention: Control group (expected 8 weeks)
Number of subjects: 239
Study 39382852 — intervention group
Group type: COMPARATOR
Intervention: Control group (expected 12 weeks)
Number of subjects: 239
Study 39382852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TAF intervention)
Number of subjects: 239
Study 39382856 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding valve (SEV)
Number of subjects: 621
Study 39382856 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable valve (BEV)
Number of subjects: 621
Study 39382898 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 60
Study 39382898 — intervention group
Group type: COMPARATOR
Intervention: In-person consultation
Number of subjects: 60
Study 39382898 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduling navigation
Number of subjects: 60
Study 39382898 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort without scheduling navigation
Number of subjects: 60
Study 39382937 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent empowerment intervention based on nursing education (PEINE)
Number of subjects: 48
Study 39382937 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 39383026 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acupuncture; details on dosage and duration not available
Number of subjects: 0
Study 39383026 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified
Number of subjects: 0
Study 39383382 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma and standard treatment
Number of subjects: 35
Study 39383382 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 35
Study 39383445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguineous cardiopulmonary bypass prime
Number of subjects: 40
Study 39383445 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory interventions targeting complement
Number of subjects: 40
Study 39383458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with elivaldogene autotemcel (eli-cel)
Number of subjects: 67
Study 39383459 — intervention group
Group type: EXPERIMENTAL
Intervention: Elivaldogene autotemcel (eli-cel) gene therapy
Number of subjects: 32
Study 39383612 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 21
Study 39383612 — intervention group
Group type: COMPARATOR
Intervention: Second-line immunosuppressants (SLI)
Number of subjects: 21
Study 39383771 — intervention group
Group type: EXPERIMENTAL
Intervention: naporafenib plus rineterkib (naporafenib 400 mg BID, rineterkib 200 mg QD)
Number of subjects: 216
Study 39383771 — intervention group
Group type: EXPERIMENTAL
Intervention: naporafenib plus trametinib (naporafenib 200 mg BID, trametinib 1 mg QD)
Number of subjects: 216
Study 39383771 — intervention group
Group type: EXPERIMENTAL
Intervention: naporafenib plus trametinib (naporafenib 400 mg BID, trametinib 0.5 mg QD)
Number of subjects: 216
Study 39384067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendakimab 360 mg once weekly for 48 weeks
Number of subjects: 399
Study 39384067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendakimab 360 mg once weekly for 24 weeks followed by cendakimab 360 mg every other week for 24 weeks (with matching placebo on alternative weeks)
Number of subjects: 399
Study 39384067 — intervention group
Group type: COMPARATOR
Intervention: Placebo once weekly for 48 weeks
Number of subjects: 399
Study 39384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoate 1000 mg/day
Number of subjects: 149
Study 39384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoate 500 mg/day
Number of subjects: 149
Study 39384087 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoate 750 mg/day
Number of subjects: 149
Study 39384087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 39384142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope-based breath test of intestinal sucrase activity
Number of subjects: 0
Study 39384194 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 (30 mg) with ipilimumab (3 mg/kg)
Number of subjects: 50
Study 39384194 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 (100 mg) with ipilimumab (3 mg/kg)
Number of subjects: 50
Study 39384194 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 with ipilimumab and SABR
Number of subjects: 50
Study 39384194 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 (30 mg) with nivolumab (480 mg) and SABR
Number of subjects: 50
Study 39384194 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986156 with ipilimumab or nivolumab
Number of subjects: 50
Study 39384203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 119
Study 39384222 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% autologous platelet-rich plasma (APRP)
Number of subjects: 96
Study 39384222 — intervention group
Group type: COMPARATOR
Intervention: 100% autologous serum (AS)
Number of subjects: 96
Study 39384223 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1 spectacle lenses
Number of subjects: 256
Study 39384223 — intervention group
Group type: COMPARATOR
Intervention: Control lenses
Number of subjects: 256
Study 39384224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-and-stand desk
Number of subjects: 0
Study 39384224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Number of subjects: 0
Study 39384224 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 39384235 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based, structured, 1-year, advanced dietary education based on a Mediterranean diet
Number of subjects: 0
Study 39384235 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (gluten-free diet without adequate dietary control)
Number of subjects: 0
Study 39384237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Number of subjects: 66
Study 39384237 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 66
Study 39384241 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS+IMD 1200 mg
Number of subjects: 82
Study 39384241 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS+IMD 2400 mg
Number of subjects: 82
Study 39384241 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS+IMD (1200 mg or 2400 mg)
Number of subjects: 82
Study 39384241 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS+IMD
Number of subjects: 82
Study 39384241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 39384243 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 40
Study 39384243 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 39384245 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 64
Study 39384245 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 64
Study 39384245 — intervention group
Group type: COMPARATOR
Intervention: Sham Group (non-stimulation)
Number of subjects: 64
Study 39384245 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS and VNS
Number of subjects: 64
Study 39384342 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73m²
Number of subjects: 10205
Study 39384342 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 90 mL/min/1.73m²
Number of subjects: 10205
Study 39384342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for frailty
Number of subjects: 10205
Study 39384451 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg b.i.d.) + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Number of subjects: 743
Study 39384451 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Number of subjects: 743
Study 39384451 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib + Abiraterone
Number of subjects: 743
Study 39384451 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Abiraterone
Number of subjects: 743
Study 39384609 — intervention group
Group type: EXPERIMENTAL
Intervention: MGTA-145 (0.03 mg/kg) intravenously with plerixafor subcutaneously
Number of subjects: 25
Study 39384609 — intervention group
Group type: COMPARATOR
Intervention: Plerixafor
Number of subjects: 25
Study 39384614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal human milk (IHM) therapy
Number of subjects: 37
Study 39384614 — intervention group
Group type: COMPARATOR
Intervention: Historic HM-fed infants (Control)
Number of subjects: 37
Study 39384685 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5 (adalimumab biosimilar)
Number of subjects: 911
Study 39384691 — intervention group
Group type: EXPERIMENTAL
Intervention: Training PCPs with a half-day course on default choice approach using a decision aid (DA)
Number of subjects: 287
Study 39384691 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 1-h refresher training on smoking cessation aids
Number of subjects: 287
Study 39384712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day) with standard medical therapy (Group A)
Number of subjects: 40
Study 39384712 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard medical therapy (Group B)
Number of subjects: 40
Study 39384742 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab plus lenvatinib and TACE
Number of subjects: 38
Study 39384801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus exemestane (25mg for 3 weeks followed by 1 week off or 37.5mg continuous) for 6 months
Number of subjects: 18
Study 39384801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus exemestane
Number of subjects: 18
Study 39384859 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-Assisted Relaxation (MAR)
Number of subjects: 9
Study 39385099 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cold application (n=30)
Number of subjects: 120
Study 39385099 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat application (n=30)
Number of subjects: 120
Study 39385099 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibration application (n=30)
Number of subjects: 120
Study 39385099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 39385104 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-sparing modified short-course radiotherapy (25 Gy/5 fractions, 5 Gy/f) followed by CAPOX and tislelizumab
Number of subjects: 32
Study 39385217 — intervention group
Group type: COMPARATOR
Intervention: OD(-) group (withdrawal of life-sustaining therapies without planned organ donation)
Number of subjects: 206
Study 39385217 — intervention group
Group type: EXPERIMENTAL
Intervention: OD(+) group (withdrawal of life-sustaining therapies with planned organ donation)
Number of subjects: 206
Study 39385223 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity supervised aerobic training for six months
Number of subjects: 50
Study 39385224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient plus ultra-processed warning labels
Number of subjects: 1004
Study 39385224 — intervention group
Group type: COMPARATOR
Intervention: Nutrient warning labels
Number of subjects: 1004
Study 39385279 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion-focused cognitive behavioral therapy (cf-CBT)
Number of subjects: 368
Study 39385279 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting skills training (PST)
Number of subjects: 368
Study 39385279 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management (CM)
Number of subjects: 368
Study 39385279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cf-CBT, PST, and CM
Number of subjects: 368
Study 39385279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 368
Study 39385323 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction (DBR)
Number of subjects: 191
Study 39385323 — intervention group
Group type: EXPERIMENTAL
Intervention: Central-axial single-bundle reconstruction (CASBR)
Number of subjects: 191
Study 39385323 — intervention group
Group type: COMPARATOR
Intervention: Anatomical single-bundle reconstruction (ASBR)
Number of subjects: 191
Study 39385323 — intervention group
Group type: EXPERIMENTAL
Intervention: DBR
Number of subjects: 191
Study 39385323 — intervention group
Group type: EXPERIMENTAL
Intervention: CASBR
Number of subjects: 191
Study 39385323 — intervention group
Group type: COMPARATOR
Intervention: ASBR
Number of subjects: 191
Study 39385327 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus non-steroidal aromatase inhibitor (anastrozole or letrozole)
Number of subjects: 311
Study 39385327 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 311
Study 39385327 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 311
Study 39385523 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62% (40.5 mg/day for 16 weeks)
Number of subjects: 246
Study 39385523 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62%
Number of subjects: 246
Study 39385595 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (6 g)
Number of subjects: 20
Study 39385595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g of corn starch)
Number of subjects: 20
Study 39385752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine (DTaP-IPV-HB-Hib)
Number of subjects: 100
Study 39385752 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent vaccine (DTwP-HB-Hib)
Number of subjects: 100
Study 39385774 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic associations with obesity-related SNPs and PRS
Number of subjects: 151
Study 39385774 — intervention group
Group type: EXPERIMENTAL
Intervention: Food cues exposure during fMRI
Number of subjects: 151
Study 39385952 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal GM stress
Number of subjects: 159
Study 39385952 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal GM stress
Number of subjects: 159
Study 39385952 — intervention group
Group type: EXPERIMENTAL
Intervention: GM resilience
Number of subjects: 159
Study 39386177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Tacrosolv (5 µg tacrolimus/eye/day)
Number of subjects: 64
Study 39386177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 39386211 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous anti-CD20 CAR T cells manufactured using CliniMACS Prodigy®
Number of subjects: 0
Study 39386444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy with letrozole
Number of subjects: 32
Study 39386444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of mitochondrial complex I
Number of subjects: 32
Study 39386444 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (letrozole)
Number of subjects: 32
Study 39387110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 480
Study 39387110 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase
Number of subjects: 480
Study 39387205 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised optimised diet (PD) incorporating two plant protein fibre (PPF) products
Number of subjects: 180
Study 39387205 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) programme
Number of subjects: 180
Study 39387205 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised optimised diet (PD) + Physical activity (PA) programme
Number of subjects: 180
Study 39387205 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 180
Study 39387211 — intervention group
Group type: EXPERIMENTAL
Intervention: WEAR + conventional rehabilitation (WG)
Number of subjects: 127
Study 39387211 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CG)
Number of subjects: 127
Study 39387227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (not specified in detail)
Number of subjects: 0
Study 39387403 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 39387403 — intervention group
Group type: COMPARATOR
Intervention: Other disease-modifying antirheumatic drugs
Number of subjects: 0
Study 39387441 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (oral), dose-escalation in second-line treatment
Number of subjects: 0
Study 39387441 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (oral), dose-escalation in first-line treatment
Number of subjects: 0
Study 39387766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 12097
Study 39387766 — intervention group
Group type: COMPARATOR
Intervention: Renin-angiotensin system inhibitor (RASi)
Number of subjects: 12097
Study 39387771 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAD-TX (intervention arm using HFMS data)
Number of subjects: 522
Study 39387771 — intervention group
Group type: COMPARATOR
Intervention: BMAD-HF (control arm without HFMS data)
Number of subjects: 522
Study 39387783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile score
Number of subjects: 2023
Study 39387783 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 2023
Study 39387783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostar
Number of subjects: 2023
Study 39387783 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTA
Number of subjects: 2023
Study 39387783 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 2023
Study 39387783 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic curves
Number of subjects: 2023
Study 39387937 — intervention group
Group type: EXPERIMENTAL
Intervention: External electrical cardioversion (EC)
Number of subjects: 43
Study 39387937 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular node ablation
Number of subjects: 43
Study 39387999 — intervention group
Group type: EXPERIMENTAL
Intervention: CBO-based implementation of Keep It Up!
Number of subjects: 62
Study 39388024 — intervention group
Group type: EXPERIMENTAL
Intervention: VenKd (venetoclax + carfilzomib + dexamethasone)
Number of subjects: 57
Study 39388024 — intervention group
Group type: COMPARATOR
Intervention: Kd (carfilzomib + dexamethasone)
Number of subjects: 57
Study 39388061 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography-based wristband (CardioWatch 287-2, Corsano Health)
Number of subjects: 100
Study 39388061 — intervention group
Group type: COMPARATOR
Intervention: Nellcor fingerclip and 5-lead ECG (QMAPP Haemodynamic Monitoring module, Fysicon B.V.)
Number of subjects: 100